Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.
The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).
The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.
For recent media coverage of Bioniche Life Sciences Inc. click here >>
April 15, 2014
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business
April 14, 2014
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business
April 3, 2014
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction